GLP-1s and Muscle Loss; ‘Ozempic Personality’; Acromegaly and Cancer Risk

Real-world data suggested the dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) was associated with greater weight loss, but also muscle loss, compared with semaglutide (Ozempic, Wegovy), according to a medical records analysis published as a medRxiv preprint.

Fructose may drive certain features of metabolic syndrome by promoting triglyceride synthesis and fat accumulation, according to a review. (Nature Metabolism)

Researchers detailed how a ketogenic diet may improve beta-cell function in people with diabetes by way of proinsulin-C-peptide ratio, a biomarker of pancreas stress. (Journal of the Endocrine Society)

Anecdotal reports from doctors and patients suggest GLP-1 drugs may cause a type of emotional flattening dubbed “Ozempic personality.” (Washington Post)

Patients had significantly higher risks for cancer in the years before their acromegaly diagnosis, a nationwide Swedish study found. (Journal of Clinical Endocrinology & Metabolism)

Meanwhile, experts in the same journal reviewed current controversies in acromegaly care.

The GLP-1 pill orforglipron (Foundayo) significantly reduced risks for adverse cardiac events and mortality versus insulin glargine in a phase III trial of adults with type 2 diabetes and obesity or overweight plus high cardiovascular risk, said Eli Lilly.

The American Association of Clinical Endocrinology released an update to its algorithm for managing adults with type 2 diabetes. (Endocrine Practice)

Madison Warner, the daughter of Sen. Mark Warner (D-Va.), died at age 36 after battling type 1 diabetes and other health problems for decades. (The Hill)

An investigational vaginal probiotic capsule for in vitro fertilization-related embryo implantation failure proved safe and well tolerated and will advance to a phase II trial, said developer Freya Biosciences.

While patients with metabolically unhealthy obesity had the highest risk, those with metabolically healthy obesity still had an elevated risk of developing cardiovascular disease over 20 years compared with healthy, normal-weight individuals. (International Journal of Obesity)